Beranda › Sindrom Mielodisplastik › Kansas

Uji klinis Sindrom Mielodisplastik di Kansas

5 studi untuk Sindrom Mielodisplastik mencari peserta di lokasi di Kansas.

Kota di Kansas

Teks studi resmi (Bahasa Inggris)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06577441

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Kansas Clinical Research Center, Fairway
HaysMed, Hays
University of Kansas Cancer Center, Kansas City
dan 7 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

University of Kansas Medical Center Research Institute, Inc., Kansas City

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06146257

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Cancer Center, Westwood

Menerima pesertaFase 1

Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Mar 2026 · NCT03533816

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

University of Kansas Cancer Center, Fairway

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jun 2020 · NCT04167696

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.